Matt Hoffman, Associate Editorial Director for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He executive produces the NeurologyLive Mind Moments® podcast, and hosted the Medical World News show Deep Dive. Follow him on Twitter @byMattHoffman or email him at mhoffman@neurologylive.com
FDA Approves Extended-Release Deutetrabenazine for Huntington Disease Chorea, Tardive Dyskinesia
February 17th 2023Teva’s VMAT2 inhibitor was previously approved in a twice-daily formulation. The once-daily extended-release treatment, marketed as Austedo XR, is expected to be available later in 2023 in doses of 6 mg, 12 mg, and 24 mg.
National Women Physicians Day: 10 Moments That Matter in Medicine
February 3rd 2023The list of women's contributions to the field of medicine is a long one, encompassing the hard work of hundreds of individuals. To highlight some of these pioneers, NeurologyLive® has compiled a timeline of 10 of the moments that matter in the history of women in medicine.
Insights Into the Current and Future Treatment of Myasthenia Gravis
January 18th 2023James F. Howard Jr, MD, and Nicholas J. Silvestri, MD, FAAN, offer their experiences in treating patients with myasthenia gravis and their thoughts on the future of the care paradigm with novel agents in development.
Advances in Myositis and Lingering Unmet Needs Ahead of MDA 2023
January 10th 2023Angela Lek, PhD, and Tahseen Mozaffar, MD, offered their insight into myositis and the clinical needs for the population, ahead of a focused session on it, chaired by Mozzafar at the MDA’s Clinical & Scientific Conference.
Prioritizing Sleep Health From a Public Health Standpoint
December 23rd 2022The past year has provided great steps forward in sleep science, and coupled with the lingering difficulties in care and the COVID-19 pandemic’s effects, the field is coming to a head to make sleep health a public health priority.
Building the Biomarker Panel in Neurology: Glial Fibrillary Acidic Protein
December 9th 2022As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased, and in recent years, GFAP has emerged as a valuable candidate to add to the existing panel.